AbbVie Inc. EBIT Margin

EBIT Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.

Highlights and Quick Summary

  • EBIT Margin for the quarter ending June 29, 2020 was 7.21% (a -82.75% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by -76.64%
  • Annual EBIT Margin for 2019 was 39.03% (a 100.26% increase from previous year)
  • Annual EBIT Margin for 2018 was 19.49% (a -42.39% decrease from previous year)
  • Annual EBIT Margin for 2017 was 33.83% (a -7.14% decrease from previous year)
  • Twelve month EBIT Margin ending June 29, 2020 was 30.17% (a -24.31% decrease compared to previous quarter)
  • Twelve month trailing EBIT Margin increased by 50.55% year-over-year
Trailing EBIT Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
30.17% 39.86% 39.03% 20.04%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of AbbVie Inc.

Most recent EBIT Marginof ABBV including historical data for past 10 years.

Interactive Chart of EBIT Margin of AbbVie Inc.

AbbVie Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 7.21% 41.8%
2019 45.45% 30.86% 41.19% 38.45% 39.03%
2018 -29.39% 38.36% 33.37% 36.59% 19.49%
2017 23.03% 38.51% 38.34% 36.82% 33.83%
2016 34.05% 36.71% 37.0% 38.23% 36.43%
2015 33.02% 31.71% 33.83% 33.47% 32.97%
2014 -7.61% 19.13% 30.76% 29.61% 17.09%
2013 30.03% 29.43% 30.97% 30.15% 30.14%
2012 34.98% 35.4% 31.65% 23.44% 31.65%
2011 -121.03% 100.0% 100.0% 21.16% 20.75%
2010 30.16%
2009 34.7%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.